I Found a overview of the Frost & Sullivan Report.
MOUNTAIN VIEW, Calif., Sept. 10 /PR Newswire/ -- Diabetes is the fourth-leading cause of death in the United States, taking the lives of 385,000 Americans. Direct and indirect costs due to diabetes and its complications exceed 90 billion annually. However the most staggering figure about diabetics is only half of them have been diagnosed. With baby boomers entering the prime age to be diagnosed with diabetes, it is becoming more important than ever to be able to successfully monitor and diagnosis the disease.
According to The U.S. Diabetes Diagnostic and Monitoring Market, strategic research by Frost & Sullivan, devices used to diagnosis and monitor diabetes is expected to be a $877.2 million market in 1997. Long-term growth in this market is dependent on the diagnosis of the nearly 8 million diabetics who are unaware of the disease, and improving the monitoring habits of diagnosed diabetics through increased patient education.
Two primary company strategies are becoming prevalent in this market. First, to provide more comprehensive care to patients, companies have taken part in a series of partnerships and joint-ventures of companies in the various segments of the total diabetes industry. Second, to increase the installed base of systems and meters, and be able to make profits selling the necessary support equipment, companies have been offering systems and meters at virtually no cost to the end-user.
The study divides this market into monitoring devices and aids which allow individuals to monitor their own glucose levels, and clinical laboratory tests, which are used by general practitioners and research laboratories to diagnosis the disease and patients' glucose levels.
The monitoring devices and aids segment holds a great majority of the market share at 89.4 percent and includes blood glucose meters, blood glucose test strips, diabetes lancets, and lancing devices. The market has experienced substantial growth since the release of the Diabetes Control and Complications Trials (DCCT) in 1993. This ten-year study showed that keeping blood sugar concentration as close to normal, non-diabetic levels as possible slows the onset and progression of complications caused by the disease. The DCCT recommends regular monitoring of blood glucose levels, and sparking an increase in diabetes education.
Yet 82 percent of diagnosed diabetics still do not monitor their blood glucose levels, representing a great market opportunity for those who can capitalize on this untapped population. Competitors are continually trying to make innovations in monitoring devices, including moving from photo reflectance-based meters to electrochemical biosensors and providing more extensive memory and testing features in their products.
Non and semi-invasive meters are seen as the next step in this market and several companies are going to great expense to make them a reality. Not only would these meters take significant market share from their invasive counterparts, but would eliminate the need for lancets and lancing devices.
As a whole, the clinical laboratory tests market, which contains blood reagents and glycohemoglobin tests, generates 10.6 percent of the U.S. diabetes diagnosis and monitoring market. Although blood reagents tests are more established, through the DCCT, glycohemoglobin was proven to be a very effective test to monitor a diabetics health over a three month period. Cost cutting managed care was impressed by the results and were encouraged by the prospect of testing diabetics only four times a year instead of twelve with blood reagents tests.
With only 40 percent of diagnosed diabetics regularly monitor their blood glucose level through the clinical lab segment, there is still a large patient population available for competitors to reach.
U.S. Diabetes Diagnostic and Monitoring Market, contains an in-depth analysis of the market, including competitive benchmarking, technology trends, and market forecasts into the year 2004. The study also provides exhaustive customer demographics including number of diagnosed/undiagnosed diabetics, breakdown by the type of the disease, and the monitoring behavior of the patients were taken into consideration.
Selected technologies, products, and subjects found in the study include blood glucose reagent test, glycohemoglobin tests, boronate affinity chromatography, ion exchange liquid chromatography, electrophoresis products, immunoassay products, blood glucose meters, electrochemical sensors, photo reflective sensors, no-wipe/no-timing technology, non-invasive blood glucose testing, home glycohemoglobin testing, blood glucose test strips, diabetes lancets, lancing devices, diabetes mellitus, insulin dependent diabetes mellitus, gestational diabetes mellitus, and diabetes insipidus.
Participants mentioned in this study include Abaxis Inc., Abbott Laboratories, Bayer Corporation, Beckman Instruments Inc., Becton Dickinson and Company, Bio-Rad Laboratories, Boehringer Mannheim Corporation, Can-Am Care Corporation, Cascade Medical Inc., Chronimed Inc., Dade International, Eppendorf Scientific Inc., Gainor Medical USA Inc., Helena Laboratories, HemoCue Inc., Home Diagnostics Inc., Instrumentation Laboratory, Isolab Inc., Johnson & Johnson, Clinical Diagnostics Inc., LifeScan Inc., Lukens/Ulster Medical Corporation, Marquette Medical Systems, MediSense, Inc. (Subsidary of Abbott Laboratories), Nova Biomedical, Olympus America Inc., Owen Mumford Inc., Palco Laboratories, Pierce Chemical Company (division of Perstorp Biotec), Pointe Scientific, Precision Systems Inc, Primus Corporation, Roche Diagnostic Systems Inc., Selfcare Inc., Stat Medical Devices, YSI, Inc., Amylin Pharmaceuticals, Biocontrol Technology Inc., Futrex Inc., Integ Inc., International Technidyne Corp, LXN Corporation, Novo Nordisk Pharmaceuticals Inc., SmithKline Beecham Pharmaceuticals, SpectRx, and Technical Chemicals and Products Inc.
Frost & Sullivan is an international marketing consulting company that monitors the medical industry for market trends, market measurements, and strategies. The ongoing research is utilized to update a series of research publications such as #5070-45, Diabetes Products, and to support industry participants with customized consulting needs.
Report: 5663-45
Publication Date: September 1997
Visit the Frost & Sullivan web site: frost.com
SOURCE Frost & Sullivan
-0- 09/10/97 /NOTE TO EDITORS: Free executive summaries are available to the press/
/CONTACT: Keith Hammond of Frost & Sullivan, 650-237-4384, or fax, 650-903-0915, or khammond@frost.com, or web site, frost.com
CO: Frost & Sullivan ST: California IN: HEA MTC PUB SU:
Now if I could only find the whole thing. |
